Clinical Trial for Ovarian Cancer (OvaRex®)

NCT00050375 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 354

Last updated 2007-12-18

No results posted yet for this study

Summary

This study will compare the time to disease relapse between OvaRex® MAb-B43.13-treated patients and placebo-treated patients. This study will also compare assessments of survival, quality of life, immune response and safety between active and placebo groups.

Conditions

Interventions

DRUG

oregovomab

Sponsors & Collaborators

  • Unither Pharmaceuticals

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-12-31
Completion
2007-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00050375 on ClinicalTrials.gov